ASTRAZENECA AB

Their core work

AstraZeneca is a global biopharmaceutical company headquartered in Sweden, contributing deep drug discovery and development expertise to European research consortia. Within H2020, they focus on translational safety, clinical biomarker validation, health data interoperability (FAIR/OMOP), and disease-area research spanning oncology, neuroscience, respiratory disease, and liver conditions. They bring industrial-scale pharmaceutical R&D capabilities — including compound libraries, preclinical models, and patient data assets — into public-private partnerships, particularly through IMI2 (Innovative Medicines Initiative) projects. Their participation bridges the gap between academic research and real-world drug development pipelines.

What they specialise in

How they've shifted over time

In the early period (2015–2018), AstraZeneca's H2020 work centered on translational safety, regulatory science, adaptive clinical trial design, and Alzheimer's neuroinflammation research (TREM2, LOAD). By the later period (2019–2023), the focus shifted markedly toward imaging, deep learning, clinical biomarkers, and health data interoperability — reflecting the broader pharma industry pivot toward AI-driven drug development and real-world evidence. Their MSCA training networks also evolved from pure chemistry (isotopic labeling, catalysis) toward computational and data science applications.

AstraZeneca is investing heavily in data-driven drug development — partners offering AI/ML capabilities, imaging biomarkers, or FAIR data infrastructure are likely well-positioned for future collaboration.

How they like to work

AstraZeneca never coordinates H2020 projects — they participate as a large industrial partner in consortia, typically contributing proprietary data, compound libraries, and clinical development expertise. With 686 unique partners across 34 countries, they operate as a high-connectivity hub, joining large public-private consortia (especially IMI2 projects with 20+ partners). This means working with them requires fitting into established consortium frameworks rather than bilateral arrangements.

Exceptionally broad network of 686 unique consortium partners spanning 34 countries, making them one of the most connected pharmaceutical participants in H2020. Their partnerships are heavily weighted toward Western European academic medical centers and other large pharma companies through IMI2 consortia.

What sets them apart

AstraZeneca brings something few academic partners can: real pharmaceutical pipeline data, compound screening infrastructure, and clinical trial operations at industrial scale. Their consistent participation across IMI2 projects means they have deep experience navigating EU public-private partnership structures. For consortium builders, they offer credibility with reviewers and access to proprietary datasets that would otherwise be impossible to include in publicly funded research.

Highlights from their portfolio

• EHDEN
  Major EU health data harmonization initiative using OMOP/OHDSI standards — positions AstraZeneca at the center of Europe's federated real-world evidence infrastructure.
• eTRANSAFE
  Flagship IMI2 project integrating preclinical safety data across pharma companies — rare example of competitors sharing toxicology data for collective benefit.
• Highlift
  Their only non-health project (industrial heat pumps) with the highest single EC contribution at EUR 930K — a surprising diversification into clean energy technology.